HRX-0233

Kundenbewertung

Based on 1 Customer Validation

HRX-0233 is a small-molecule MAP2K4 inhibitor. HRX-0233 results in strong tumor shrinkage without any apparent toxicity in H358 KRASG12C-mutant non-small cell lung cancers (NSCLC) in vivo. HRX-0233 efficiently prevents feedback activation of receptor tyrosine kinases (RTKs) upon monotherapy KRAS inhibitor Sotorasib (HY-114277) and causes a more sustained and complete inhibition of MAPK signaling. HRX-0233 is promising for research of AR-negative prostate cancer, lung and colon cancers.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: 98.92%
  • CAS. Nr.: 2409140-12-9
  • Formel: C24H21F2N5O3S
  • Molecular Weight:497.52
  • Speicherung:
    Powder   -20°C, 3 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
100 mg

Angebot einholen Auf Lager

Please select quantity
Amount: USD 0.00